Am J Psychiatry 158:1974-1981, December 2001
© 2001 American Psychiatric Association
Efficacy of Sertraline in Preventing Relapse of Posttraumatic Stress Disorder: Results of a 28-Week Double-Blind, Placebo-Controlled Study
Jonathan Davidson, M.D.,
Teri Pearlstein, M.D.,
Peter Londborg, M.D.,
Kathleen T. Brady, M.D.,
Barbara Rothbaum, Ph.D.,
Jon Bell, M.D.,
Richard Maddock, M.D.,
Mark T. Hegel, Ph.D., and
Gail Farfel, Ph.D.
OBJECTIVE: The study examined the efficacy of sertraline, compared with placebo, in sustaining improvement and preventing relapse over 28 weeks in patients with posttraumatic stress disorder (PTSD) who had completed a 12-week double-blind, placebo-controlled acute treatment study and a subsequent 24-week open-label study of continuation treatment with sertraline. METHOD: Ninety-six patients were randomly assigned, in a double-blind design, to 28 weeks of maintenance treatment with sertraline (50–200 mg, N=46; 78% were women) or placebo (N=50; 62% were women). Measures used in biweekly assessments included the Clinician-Administered PTSD Scale, the Impact of Event Scale, and the Clinical Global Impression severity and improvement ratings. Kaplan-Meier analyses were used to estimate time to discontinuation from the study due to relapse, relapse or study discontinuation due to clinical deterioration, and acute exacerbation. RESULTS: Continued treatment with sertraline yielded lower PTSD relapse rates than placebo (5% versus 26%). Patients who received placebo were 6.4 times as likely to experience relapse as were patients who received sertraline. Kaplan-Meier analyses confirmed the protective effect of sertraline in significantly extending time in remission. The ability of sertraline to sustain improvement was comparable across the three core PTSD symptom clusters (reexperiencing/intrusion, avoidance/numbing, and hyperarousal). A regression analysis found early response during acute treatment to be associated with a more than 16-fold reduced risk of relapse after placebo substitution. Sertraline, at a mean endpoint dose of 137 mg, was well tolerated, with no sertraline-related adverse events observed at a rate of 10% or higher. CONCLUSIONS: The results provide evidence for the ability of sertraline both to sustain improvement in PTSD symptoms and to provide prophylactic protection against relapse.
This article has been cited by other articles:
|
|
|
|
 
A. J. Rush, S. R. Wisniewski, D. Warden, J. F. Luther, L. L. Davis, M. Fava, A. A. Nierenberg, and M. H. Trivedi
Selecting Among Second-Step Antidepressant Medication Monotherapies: Predictive Value of Clinical, Demographic, or First-Step Treatment Features
Arch Gen Psychiatry,
August 1, 2008;
65(8):
870 - 880.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. I. Bisson
Pharmacological treatment of post-traumatic stress disorder
Advan. Psychiatr. Treat.,
March 1, 2007;
13(2):
119 - 126.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. S. Baldwin, I. M. Anderson, D. J. Nutt, B. Bandelow, A. Bond, J. R. T. Davidson, J. A. den Boer, N. A. Fineberg, M. Knapp, J. Scott, et al.
Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology
J Psychopharmacol,
November 1, 2005;
19(6):
567 - 596.
[Abstract]
[PDF]
|
|
|
|
|
|
|
F. B. Schoenfeld, C. R. Marmar, and T. C. Neylan
Current Concepts in Pharmacotherapy for Posttraumatic Stress Disorder
Psychiatr Serv,
May 1, 2004;
55(5):
519 - 531.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Zatzick, P. Roy-Byrne, J. Russo, F. Rivara, R. Droesch, A. Wagner, C. Dunn, G. Jurkovich, E. Uehara, and W. Katon
A Randomized Effectiveness Trial of Stepped Collaborative Care for Acutely Injured Trauma Survivors
Arch Gen Psychiatry,
May 1, 2004;
61(5):
498 - 506.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. R.T. Davidson, D. J. Stein, A. Y. Shalev, and R. Yehuda
Posttraumatic Stress Disorder: Acquisition, Recognition, Course, and Treatment
J Neuropsychiatry Clin Neurosci,
May 1, 2004;
16(2):
135 - 147.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Cohen, Z. Kaplan, M. Kotler, I. Kouperman, R. Moisa, and N. Grisaru
Repetitive Transcranial Magnetic Stimulation of the Right Dorsolateral Prefrontal Cortex in Posttraumatic Stress Disorder: A Double-Blind, Placebo-Controlled Study
Am J Psychiatry,
March 1, 2004;
161(3):
515 - 524.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. R. T. Davidson
Effective Management Strategies for Posttraumatic Stress Disorder
Focus,
July 1, 2003;
1(3):
239 - 243.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. M. Connor and M. I. Butterfield
Posttraumatic Stress Disorder
Focus,
July 1, 2003;
1(3):
247 - 262.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. I Butterfield
Fluoxetine may prevent relapse in post traumatic stress disorder
Evid. Based Ment. Health,
May 1, 2003;
6(2):
51 - 51.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. I Bisson
Sertraline maintenance treatment reduced relapse and dropouts in post-traumatic stress disorder
Evid. Based Ment. Health,
November 1, 2002;
5(4):
110 - 110.
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. MARTENYI, E. B. BROWN, H. ZHANG, S. C. KOKE, and A. PRAKASH
Fluoxetine v. placebo in prevention of relapse in post-traumatic stress disorder
The British Journal of Psychiatry,
October 1, 2002;
181(4):
315 - 320.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. B. Stein
A 46-Year-Old Man With Anxiety and Nightmares After a Motor Vehicle Collision
JAMA,
September 25, 2002;
288(12):
1513 - 1521.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. I Bisson
Sertraline maintenance treatment reduced relapse and dropouts in post-traumatic stress disorder
Evid. Based Med.,
September 1, 2002;
7(5):
149 - 149.
[Full Text]
[PDF]
|
|
|
|
|
|
|
PTSD: Successful Relapse Prevention
Journal Watch Women's Health,
January 18, 2002;
2002(118):
4 - 4.
[Full Text]
|
|
|
Get information about faster international access.
Privacy Policy
Copyright © 2001
American Psychiatric Association.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|
